AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 16287954
Drug: Usual-dose simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Usual-dose simvastatin (20 mg/d; n = 4449)
Trial: 16287954
Drug: Usual-dose simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Usual-dose simvastatin (20 mg/d)
Trial: 12221217
Drug: Milk-based protein
RxNorm normalized name: milk protein concentrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milk-based protein (MP) 40 g daily for 3 months
Trial: 74730
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg oestradiol in viscous gel
Trial: 74730
Drug: Viscous gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Viscous gel alone
Trial: 29891610
Drug: Doravirine 100
RxNorm normalized name: doravirine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doravirine 100 mg
Trial: 18842612
Drug: Weekly paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Weekly paclitaxel (Pw) vs GDoc
Trial: 15243470
Drug: Pilocarpine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pilocarpine (5 mg, PILO, n=29)
Trial: 15243470
Drug: Pilocarpine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pilocarpine (5 mg, PILO)
Trial: 11679972
Drug: High-dose interferon
RxNorm normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose interferon induction therapy (Group A: 10 MU IntronA/day for 2 weeks, then 10 MU/2 days for 12 weeks)
Trial: 11679972
Drug: Low-dose interferon
RxNorm normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose interferon therapy (Group B: 5 MU/day for 14 weeks)
Trial: 11679972
Drug: Low-dose interferon
RxNorm normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose interferon therapy (Group C: 5 MU/2 days for 14 weeks)
Trial: 11679972
Drug: High-dose interferon
RxNorm normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose interferon induction therapy (Group A) in genotype 1 patients
Trial: 11679972
Drug: Low-dose interferon
RxNorm normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose interferon therapy (Group B) in genotype 1 patients
Trial: 11679972
Drug: Low-dose interferon
RxNorm normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose interferon therapy (Group C) in genotype 1 patients
Trial: 11679972
Drug: High-dose interferon
RxNorm normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose interferon induction therapy (Group A) in genotype 3a patients
Trial: 11679972
Drug: Low-dose interferon
RxNorm normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose interferon therapy (Group B) in genotype 3a patients
Trial: 11679972
Drug: Low-dose interferon
RxNorm normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose interferon therapy (Group C) in genotype 3a patients
Trial: 9597561
Drug: OROS formulation
RxNorm normalized name: Oro Clense
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OROS formulation (75 mg)
Trial: 9597561
Drug: IR formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IR formulation (75 mg)
Trial: 8169026
Drug: Capsaicin cream
RxNorm normalized name: CAPSAICIN 0.1 g in 100 g TOPICAL CREAM [Capsaicin Cream]
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Capsaicin cream applied for 3 weeks
Trial: 25287214
Drug: Ponesimod 100
RxNorm normalized name: ponesimod
DrugBank: Ponesimod (DB12016)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ponesimod 100 mg
Trial: 23597235
Drug: Gardening intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gardening intervention including a fruit and vegetable garden, monthly curriculum, gardening support, and technical assistance
Trial: 16522412
Drug: Valacyclovir 500
RxNorm normalized name: valacyclovir 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valacyclovir 500 mg twice daily until delivery
Trial: 12771610
Drug: Subcutaneous enoxaparin
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous enoxaparin 40 mg daily
Trial: 10695617
Drug: LAC (lansoprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LAC (lansoprazole 30 mg twice a day, amoxicillin 500 mg three times a day, clarithromycin 200 mg twice a day)
Trial: 10695617
Drug: RAC (rabeprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RAC (rabeprazole 20 mg twice a day, amoxicillin 500 mg three times a day, clarithromycin 200 mg twice a day)
Trial: 10695617
Drug: R1/2AC (rabeprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R1/2AC (rabeprazole 10 mg twice a day, amoxicillin 500 mg three times a day, clarithromycin 200 mg twice a day)
Trial: 16501426
Drug: Aspirin plus
RxNorm normalized name: Aspirin Plus Antacid Extra Strength
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin plus heparin
Trial: 3915886
Drug: Tenoxicam (continued
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tenoxicam (continued treatment)
Trial: 30265040
Drug: Concurrent Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent Treatment of PTSD and SUD Using Prolonged Exposure (COPE)
Trial: 20435232
Drug: Desirudin (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desirudin (15 mg SC q12h for patients without thrombosis; 30 mg SC q12h for patients with thrombosis)
Trial: 20435232
Drug: Argatroban (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Argatroban (administered by continuous intravenous infusion according to approved prescribing information or institutional guidelines)
Trial: 12452228
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (15 mg/kg intravenously before skin incision and a second bolus of 15 mg/kg at the end of CPB)
Trial: 12452228
Drug: Saline placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline placebo (administered at the end of CPB)
Trial: 3440095
Drug: Morning dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morning dosing of theophylline
Trial: 3440095
Drug: Evening dosing
RxNorm normalized name: Evening Dosing 24 HR Jornay 60 MG Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evening dosing of theophylline
Trial: 3440095
Drug: Both morning
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both morning and evening dosing of theophylline
Trial: 12623326
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of tea catechin extracts (3.7 g/L catechins, 43% epigallocatechin gallate), three times daily for four weeks.
Trial: 12623326
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of saline/bromhexine alone (control group).
Trial: 12623326
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of tea catechin extracts.
Trial: 10874805
Drug: Commercially pure
RxNorm normalized name: Dream Pure BB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Commercially pure titanium implants
Trial: 10874805
Drug: Coated implants
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coated implants
Trial: 18261121
Drug: Implant sites
RxNorm normalized name: PAD,BITE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implant sites
Trial: 9169208
Drug: Presentation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Presentation of compounds with conflicting reinforcement histories
Trial: 9169208
Drug: Presentation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Presentation of compounds containing some or all novel components
Trial: 8249176
Drug: IL-2 plus
RxNorm normalized name: IL-2
DrugBank: Human interleukin-2 (DB14865)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL-2 plus low-dose MPA (500 mg orally one day/week)
Trial: 8249176
Drug: IL-2 alone
RxNorm normalized name: Ile
DrugBank: Isoleucine (DB00167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IL-2 alone (3 million IU twice/day for 5 days/month subcutaneously)
Trial: 8249176
Drug: IL-2 plus
RxNorm normalized name: IL-2
DrugBank: Human interleukin-2 (DB14865)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL-2 plus low-dose MPA
Trial: 28437237
Drug: Hypothermia as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypothermia as adjunctive therapy to PCI
Trial: 26256131
Drug: Punica granatum
RxNorm normalized name: PUNICA GRANATUM SEED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Punica granatum peel extract (6 g of dry peel/day)
Trial: 23899894
Drug: Terbutaline (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbutaline (8 mg)
Trial: 16710647
Drug: Pulsed infrared
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsed infrared light therapy (PILT) administered to one foot, 24 treatments (3 times/week for 8 weeks, 30 min each).
Trial: 16710647
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no treatment) on the other foot.
Trial: 14562491
Drug: Educational intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Educational intervention (weekly psychoeducation classes focused on nutrition, exercise, and healthy lifestyle)
Trial: 10758470
Drug: Epidural diamorphine
RxNorm normalized name: Diamorphine
DrugBank: Diamorphine (DB01452)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural diamorphine 2.5 mg followed by PCA bolus 1 mg with a 20‐min lockout (Gp1)
Trial: 10758470
Drug: Subcutaneous diamorphine
RxNorm normalized name: Diamorphine
DrugBank: Diamorphine (DB01452)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous diamorphine 2.5 mg followed by PCA bolus with a 10‐min lockout period (Gp2)
Trial: 10758470
Drug: Epidural diamorphine
RxNorm normalized name: Diamorphine
DrugBank: Diamorphine (DB01452)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural diamorphine 2.5 mg in 4 mL of 0.125% (w/v) bupivacaine followed by PCA bolus of 1 mg diamorphine in 4 mL 0.125% (w/v) bupivacaine with a 20‐min lockout (Gp3)
Trial: 8642363
Drug: Bodily amplification
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bodily amplification and daily life stress interaction at inception
Trial: 8642363
Drug: Four-step model
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four-step model including bodily amplification, daily life stress, age, and education level
Trial: 8642363
Drug: Bodily amplification
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bodily amplification and daily irritants interaction at baseline
Trial: 20345272
Drug: Steroid-coated (triamcinolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid-coated (triamcinolone acetonide 1%) 18F hydrophilic dilatation catheter for 2 weeks
Trial: 17127776
Drug: Intranasal midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intranasal midazolam (0.2 mg/Kg)
Trial: 17127776
Drug: Intravenous diazepam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous diazepam (0.3 mg/Kg)
Trial: 15530132
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral doses of L-T4 tablets (25, 50, 75, 100, 125, 150, 175, 200 microg per tablet; total doses 600, 625 or 700 microg)
Trial: 15530132
Drug: Liquid formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid formulation of L-T4
Trial: 3471936
Drug: Oral methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral methotrexate (n = 11)
Trial: 3471936
Drug: Intramuscular methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intramuscular methotrexate (n = 7)
Trial: 3471936
Drug: Oral methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral methotrexate (dosages ≤ 40 mg/m2)
Trial: 3471936
Drug: Oral methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral methotrexate (dosages > 40 mg/m2)
Trial: 31978697
Drug: Intranasal steroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal steroids (INS)
Trial: 31978697
Drug: Antihistamine (ATH)
RxNorm normalized name: Ahist Antihistamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihistamine (ATH) combined with leukotriene receptor antagonists (LRA)
Trial: 31819385
Drug: Tai Chi
RxNorm normalized name: Ma Chi Xian
DrugBank: Purslane (DB14327)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tai Chi exercise (weekly classes and home practice for 20 weeks)
Trial: 26102257
Drug: Whole-Body Vibration
RxNorm normalized name: Insects (whole body), mite dermatophagoides farinae
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole-Body Vibration (WBV) training, twice a week for 8 months
Trial: 24858163
Drug: Peginterferon α‐2a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peginterferon α‐2a 180μg once weekly plus ribavirin daily for 24 weeks (genotypes 2 and 3) or 48 weeks (genotypes 1 and 4)
Trial: 19641272
Drug: Lansoprazole 15
RxNorm normalized name: lansoprazole 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 15 mg once daily for 14 days
Trial: 16280696
Drug: EPZ administered
RxNorm normalized name: Epzicom
DrugBank: Abacavir (DB01048)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: EPZ administered once daily
Trial: 16280696
Drug: ABC +
RxNorm normalized name: Abciximab
DrugBank: Abciximab (DB00054)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ABC + 3TC administered twice daily
Trial: 2139338
Drug: GR32191B (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GR32191B (80 mg; p.o.)
Trial: 2139338
Drug: GR32191B (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GR32191B (40 mg; p.o.)
Trial: 2139338
Drug: Glyceryl trinitrate
RxNorm normalized name: Glyceryl trinitrate
DrugBank: Nitroglycerin (DB00727)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glyceryl trinitrate (1 mg sub-lingually)
Trial: 28221062
Drug: Concurrent Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent Treatment of PTSD and Substance Use Disorders Using Prolonged Exposure
Trial: 21752262
Drug: Inhaled nitric
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nitric oxide (iNO) at 80 ppm
Trial: 19770281
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment with S/pre‐S1/pre‐S2 vaccine and lamivudine
Trial: 19770281
Drug: Vaccine monotherapy
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine monotherapy
Trial: 15578399
Drug: Doxycycline 100
RxNorm normalized name: doxycycline 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline 100 mg po b.i.d. for 30 days
Trial: 15578399
Drug: Doxycycline 100
RxNorm normalized name: doxycycline 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline 100 mg po b.i.d. for 45 days
Trial: 15578399
Drug: Doxycycline treatment
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxycycline treatment for 45 days
Trial: 8044602
Drug: tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tranexamic acid 1 g three times daily
Trial: 2117858
Drug: Metrifonate (MT,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metrifonate (MT, 10 mg/kg body weight)
Trial: 2117858
Drug: Praziquantel (PR,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Praziquantel (PR, 40 mg/kg body weight)
Trial: 31273511
Drug: HAI raltitrexed
RxNorm normalized name: raltitrexed
DrugBank: Raltitrexed (DB00293)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HAI raltitrexed (3 mg/m2 over 1 h) followed by oxaliplatin (130 mg/m2 over 2 h) every 3 weeks
Trial: 21047395
Drug: Olanzapine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine (5 to 20 mg/day) for 24 to 28 weeks
Trial: 16202527
Drug: Bupivacaine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine (0.5 ml of 0.5% per trigger point)
Trial: 8955972
Drug: Granisetron 40
RxNorm normalized name: Granisetron
DrugBank: Granisetron (DB00889)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Granisetron 40 micrograms.kg-1 and dexamethasone 4 mg (Group D)
Trial: 6280600
Drug: Cefotaxime (1-g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotaxime (1-g dose)
Trial: 28186251
Drug: elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil
RxNorm normalized name: elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil 150 mg-150 mg-200 mg-300 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (single-tablet regimen)
Trial: 25658240
Drug: Black tea
RxNorm normalized name: black tea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Black tea (129 mg flavonoids)
Trial: 25799800
Drug: Topical steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical steroid (Mometasone furoate 0.1% cream) and Topical placental extract gel
Trial: 25799800
Drug: Topical steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical steroid (Mometasone furoate 0.1% cream) and Topical Tacrolimus 0.1% cream
Trial: 22736463
Drug: Supersaturated calcium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supersaturated calcium phosphate rinse (SCPR) four times daily
Trial: 22736463
Drug: Customary care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Customary care (topical mouth solutions made with salvia leaf extract, iodine-povidine, and fluconazole)
Trial: 17006401
Drug: Low-dose oral
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose oral contraceptive (LD-OC) pill
Trial: 11112975
Drug: Cochlear Implant
RxNorm normalized name: Cochlearia officinalis leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cochlear Implant (CI) users
Trial: 9207371
Drug: Itraconazole oral
RxNorm normalized name: itraconazole Oral Tablet
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Itraconazole oral solution (100-200 mg once daily for 3-8 weeks)
Trial: 9207371
Drug: Fluconazole tablets
RxNorm normalized name: Fluconazole Tablets
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluconazole tablets (100-200 mg once daily for 3-8 weeks)
Trial: 2950303
Drug: Intramuscular vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular vaccine (20 micrograms)
Trial: 2950303
Drug: Intradermal vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal vaccine (2 micrograms)
Trial: 28476039
Drug: Nano-pulse stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nano-pulse stimulation (NPS) treatment
Trial: 28476039
Drug: Control (surgery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (surgery or no treatment)
Trial: 12514443
Drug: Patient-delivered partner
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-delivered partner treatment with azithromycin (dose not specified)
Trial: 1847363
Drug: Concurrent use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent use of intraarterial hepatic 5-fluorodeoxyuridine (FdUrd) as a radiosensitizer
Trial: 26863234
Drug: l-citrulline
RxNorm normalized name: L-citrulline
DrugBank: Citrulline (DB00155)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: l-citrulline
Trial: 26863234
Drug: WBVT+l-citrulline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WBVT+l-citrulline
Trial: 22828696
Drug: Thoracic interlaminar
RxNorm normalized name: Thoracol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thoracic interlaminar epidural injections with or without steroids
Trial: 20429696
Drug: Pharmacological treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacological treatment (reference group)
Trial: 16153514
Drug: Oral anticoagulation
RxNorm normalized name: monitoring agent for oral anticoagulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral anticoagulation in patients with atrial fibrillation and echocardiographic risk factors
Trial: 10549964
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg intramuscular pethidine
Trial: 10549964
Drug: 7.5 mg
RxNorm normalized name: biotin 7.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 mg intramuscular diamorphine
Trial: 10549964
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg intramuscular pethidine
Trial: 1750603
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg intramuscular diamorphine